Does the intrauterine device carry the risk of immunity to sperm?

Advances in Contraception

Volumn 15, Issue 1, 1999, Pages 29-35

  Vural, B ^a   Vural, F ^a   Corakci A ^a   Turkoglu S ^b   Erk, A ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; SPERM ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNITY; INTRAUTERINE CONTRACEPTIVE DEVICE; NORMAL HUMAN;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAUTERINE DEVICES, COPPER; MALE; SPERMATOZOA;

EID: 0032787769     PISSN: 02674874     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006679427572     Document Type: Article

References (15)

1. Bronson R, Cooper G, Rosenfeld D. Sperm antibodies their role in infertility. Fertil Steril 1984;42:171-81.
2. Bronson RA. Antisperm antibodies - diagnosis and treatment. In: Hammond MG, Talbert LM, eds. Infertility. A Practical Guide for the Physician, 3rd edn Boston: Blackwell Scientific Publications. 1992:84-101.
3. Naz RK. Sperm surface antigens involved in mammalian fertilization, their role in contraceptive vaccine development for humans. Curr Opin Immunol. 1990;2:748-51.
4. Diekman AB, Herr JC. Sperm antigens and their use in the development of an immunocontraceptive. Am J Reprod Immunol. 1997;37:111-17.
5. Marshburn PB, Kutteh WH The role of antisperm antibodies in infertility. Fertil Steril 1994;61:799-811.
6. Dervişoǧlu AA. Family planning. In. Ministry of Health (Department of Mother and Child Health Care and Family Planning), Hacettepe Institute of Population Studies and Demographic and Health Surveys (DHS). Turkish Population and Health Survey. Maryland: Macro International Inc. 1993:37-54.
7. Alvarez F, Brache V, Fernandez E et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril. 1988;49:768-73.
8. World Health Organization. Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. Geneva: WHO. 1996.
9. 5b-9-mediated immune injury to human sperm. J Immunol. 1991;146:611-20.
10. Kutteh WH, Hatch KD, Blackwell RE, Mestecky J. Secretory immune system of the female reproductive tract. I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol. 1988;71:56-60.
11. Cunningham FG, MacDonald PC, Gant NF et al. Williams Obstetrics, 20th edn Connecticut Appleton and Lange, 1997.
12. Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility, 5th edn. Maryland: Williams and Wilkins, 1994.
13. Cunningham DS, Fulgham DL, Rayl DL, Hansen KA, Alexander NJ. Antisperm antibodies to sperm surface antigens in women with genital tract infection. Am J Obstet Gynecol. 1991;164:791-6.
14. Kutteh WH, Blackwell RE, Gore H, Kutteh CC, Carr BR, Mestecky J. Secretory immune system of the female reproductive tract. II. Local immune system in normal and infected fallopian tube Fertil Steril 1990;54:51-5.
15. Goldberg JM, Haering PL, Friedman CI, Dodds WG, Kim MH. Antisperm antibodies in women undergoing intrauterine insemination. Am J Obstet Gynecol. 1990;163:65-8.